Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study to Evaluate the Safety and Efficacy of DXC006 for Injection Combined With Immune Checkpoint Inhibitors or Platinum-Based Agents in Patients With Small Cell Lung Cancer.

NCT07559929 is registered in ClinicalTrials.gov with Hangzhou DAC Biotechnology Co., Ltd. as lead sponsor.

NCT NCT07559929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07559929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study to Evaluate the Safety and Efficacy of DXC006 for Injection Combined With Immune Checkpoint Inhibitors or Platinum-Based Agents in Patients With Small Cell Lung Cancer.
Lead sponsor
Hangzhou DAC Biotechnology Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 19, 2026
Completion date
December 30, 2030
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer